Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
α-synuclein vaccine
- Development stage
- Preclinical
- Lead developer
- AdaptVac
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AdaptVac's α-synuclein vaccine is a virus-like particle (VLP)-based active immunotherapy currently in research and pre-clinical development for the treatment of Parkinson's disease. The vaccine utilizes the company's proprietary capsid VLP (cVLP) technology to display either full-length α-synuclein or specific peptide fragments on the surface of a viral shell. This architecture is designed to induce a robust, polyclonal antibody response capable of recognizing and neutralizing various pathogenic forms of α-synuclein, including soluble oligomers and insoluble aggregates (Lewy bodies). By promoting the clearance of these toxic species and preventing their cell-to-cell transmission, the vaccine aims to slow or halt the neurodegenerative progression characteristic of Parkinson's disease and other synucleinopathies.
- Other names
- alpha-synuclein vaccineα-synuclein VLP vaccineAdaptVac alpha-synuclein vaccine
02
Targets
B-cell receptor specific for alpha-synuclein epitopesaggregated α-syn (Alpha-synuclein (α-syn))Bacteriophage Qbeta and AP205 capsid protein
Beyond the preview
Go deeper on α-synuclein vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on α-synuclein vaccine.